Cargando…

Randomized Phase IIa Clinical Study of an Anti-α(v)β(6) Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

Detalles Bibliográficos
Autores principales:	Raghu, Ganesh, Mouded, Majd, Prasse, Antje, Stebbins, Christopher, Zhao, Guolin, Song, Guochen, Arefayene, Million, Violette, Shelia M., Gallagher, Diana, Gibson, Kevin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704833/ https://www.ncbi.nlm.nih.gov/pubmed/35830489 http://dx.doi.org/10.1164/rccm.202205-0868LE

Ejemplares similares

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry
por: Zhang, David, et al.
Publicado: (2022)

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
por: Raghu, Ganesh
Publicado: (2017)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Schupp, Jonas Christian, et al.
Publicado: (2015)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Macrophage-Derived Biomarkers of Idiopathic Pulmonary Fibrosis
por: Bargagli, E., et al.
Publicado: (2011)

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
por: Leuschner, Gabriela, et al.
Publicado: (2020)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Nett, Randall J., et al.
Publicado: (2020)

Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods
por: Sun, Shulei, et al.
Publicado: (2022)

Reply: Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Porter, Joanna C., et al.
Publicado: (2022)

Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis
por: Saito, Shigeki, et al.
Publicado: (2022)

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Prasse, Antje, et al.
Publicado: (2019)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Importance of Occupational Exposure Data: A National Idiopathic Pulmonary Fibrosis Registry Perspective
por: Teoh, Alan K. Y., et al.
Publicado: (2020)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

CD71(−) Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease
por: Puxeddu, Ermanno, et al.
Publicado: (2019)

Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations
por: Leavy, Olivia C., et al.
Publicado: (2021)

Construction of potential idiopathic pulmonary fibrosis related microRNA and messenger RNA regulatory network
por: Zhang, Yu-Feng, et al.
Publicado: (2021)

From “traction bronchiectasis” to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology?
por: Piciucchi, Sara, et al.
Publicado: (2016)

Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kondoh, Yasuhiro, et al.
Publicado: (2020)

Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach
por: Faverio, Paola, et al.
Publicado: (2022)

Reply to Dutkiewicz and Mackiewicz
por: Raghu, Ganesh, et al.
Publicado: (2023)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways
por: Shaba, Enxhi, et al.
Publicado: (2021)

Reply to Nett et al.: Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Culver, Daniel A., et al.
Publicado: (2020)

The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells
por: Jäger, Benedikt, et al.
Publicado: (2021)

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
por: Rochwerg, Bram, et al.
Publicado: (2016)

Identification of a Genetic Susceptibility Locus for Idiopathic Pulmonary Fibrosis in the 16p Subtelomere Using Whole-Genome Sequencing
por: Donoghue, Lauren J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2i80l2e2dcs3vvleavvqa91hft